Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-386 Formulations in Healthy Volunteers
NCT03920579Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2019
- Primary completion
- May 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan, amlodipine and rosuvastatin in hypertension (HTN) and dyslipidemia (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area under the concentration-time curve from time zero to the last measurable concentration and Maximum plasma concentration. Status: unknown.
02
Drugs
telmisartanamlodipinerosuvastatin
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT03920579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920579.